Co-founder, Stealth Startup | Fmr. Director, Data
Science @ Johnson and Johnson
- Oscar has led AI strategic initiatives and product development across
Fortune 50 (Johnson & Johnson) and VC-backed biotech (PathAI)
companies, bringing a unique lens into the rapidly changing ecosystem of AI
for life sciences. Oscar has expertise in AI product strategy, pharma-tech
partnering, AI startup diligence, and validation and regulatory strategies.
Oscar is also passionate about startups and participating in Accelerators and
Incubators within the Cambridge / Boston community.
Experience in AI strategy
- Oscar holds a PhD in Biomedical Engineering and has conducted AI research
in industry and academia, including at MIT and Duke. Collectively, Oscar’s
research has produced 130+ articles and presentations in top-tier journals
(eg Nature Medicine, Nature Comms) as well as technical and clinical
conferences. Oscar’s experience includes AI/ML (computer vision,
generative AI, foundational models) in biopharma R&D and diagnostics
across multiple diseases (ONC, IMM, CVM, ophthalmology).
Prior research
Dr. Oscar Carrasco-Zevallos
- Strategy
Insights | Thoughts and analyses on the ever-changing AI ecosystem
- Technology
- VC & start-ups
Opinions and content are my own and do not reflect the views of my employer.
- Under construction!
Discovery &
Preclinical
Clinical
Development
Prototyping
Clinical Studies
- Clinical validation
- Regulatory strategy
& design control
Drug Development
Medical Device Development
Portfolio | Prior work using AI to accelerate medical product R&D
Featured
Case Studies
- 2022 - J&J Innovation Medicine R&D SPARK Innovation Award for groundbreaking strategies and platforms, J&J
- 2021 - Invited plenary presentation at FNIH Biomarkers Consortium Metabolic Disorders Meeting, PathAI
- 2020 - Selected for “100 Inspiring Hispanic Scientists in America,” Cell Press, PathAI
- 2019 - 1st place, Harvard-MIT Case Competition, MIT
- 2018 - National Institutes of Health NRSA F32 Individual Postdoctoral Fellowship, MIT
- 2018 - Burroughs Wellcome Fund Postdoctoral Enrichment Program Award, MIT
- 2018 - Leadership Award for Outstanding Service, Duke University
- 2017 - MIT’s Rising Star in Biomedical, MIT
- 2012 - National Science Foundation Graduate Research Fellowship, Duke University
- 2012 - Ford Foundation Predoctoral Fellowship, Duke University
- 2011 - Best Undergraduate Honors Research Thesis, Texas A&M
- 2011 - Craig C. Brown Outstanding Senior Engineer Award, Texas A&M
- 2011 to current - 10+ awards and distinctions for research presented at leading medical and technical conferences
- 2022 - Paige, Janssen team up to launch AI-powered bladder cancer test: Fierce Biotech
- 2021 - Acceptance of AI drug development tool into FDA biomarker qualification program: PR Newswire
- 2021 - Oral presentation on AI-based drug development tool: PR Newswire
- 2017 - Intraoperative Optical Coherence Tomography feature: Retina Today article
Notable Awards
Press
Select Publications and Presentations (from 130+)
- J. Iyer, ... O. M. Carrasco-Zevallos, … A. H. Beck, “AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases,” Nature
Medicine, 2024. Link to publication - A. J. Ramon, C. Parmar, O. M. Carrasco-Zevallos … K. Standish, “Development and real-time deployment of a histopathology-based deep learning algorithm for
patient pre-screening in a targeted-therapy bladder cancer clinical trial,” Nature Communications, 2024. Link to publication - B. Lutnick, … O. M. Carrasco-Zevallos, S. S. F. Yip, “A user-friendly AI system for histopathology image analysis system to accelerate pharmaceutical R&D,”
Journal of Pathology Informatics, 2023. Link to publication - J. Conway*, M. Pouryahya* … O. M. Carrasco-Zevallos … C. Chung, “Integration of Deep Learning-Based Histopathology with Transcriptomics Identifies Key
Genes Associated with Fibrogenesis in Patients with Advanced NASH,” Cell Reports Medicine, 2023. *Authors contributed equally. Link to publication - M. Carrasco-Zevallos, … K. Wack, “AI-based histologic measurement of NASH (AIM-NASH): A drug development tool for assessing clinical trial endpoints,” EASL
International Liver Congress, 2021. Oral presentation. Link to presentation - C. Shukla, O. M. Carrasco-Zevallos, …J. E. Gane, “Machine learning enables quantitative assessment of histopathologic signatures associated with ALT
normalization in chronic hepatitis B patients treated with tenofovir disoproxil fumarate (TDF),” AASLD, Boston, USA, 2020. Plenary oral presentation. Link to
presentation
- O. M. Carrasco-Zevallos, AI-enabled devices to accelerate drug development, Bioengineering Seminar Series, UIUC, 2022.
- O. M. Carrasco-Zevallos*, Asha Mahesh*, ML-Enabled Biomarkers for Clinical Trials: A Framework for Productization and Deployment, Bio-IT World, Boston, MA
2022. *Co-presenters - O. M. Carrasco-Zevallos, “AI-based assessment of NASH histology for treatment monitoring and risk stratification,” FNIH Biomarkers Consortium Metabolic
Disorders Meeting, Plenary Session, Webinar 2021. - O. M. Carrasco-Zevallos, “AI-powered computational pathology for liver diseases,” HBV Liver Forum – Intrahepatic Panel, The Forum for Collaborative Research,
Webinar, 2020. Link to presentation
Invited Talks (from 10+)
Coming soon!